Order S E, Sleeper A M, Stillwagon G B, Klein T L, Leichner P K
Johns Hopkins Oncology Center.
Oncology (Williston Park). 1989 May;3(5):115-20; discussion 122, 129-30.
Radioimmunoglobulin therapy is a new treatment modality that is easily administered, well tolerated, and can be given on an outpatient basis. It is not, however, as simplistic an approach to cancer therapy as commonly thought. It incorporates the sciences of immunology, physiology, radiobiology, chemistry, and physics, as well as oncology, all of which must be understood if radioimmunoglobulin therapy is to reach its potential. Partial and complete remissions have been achieved while the clinical teams involved in this research are still in the process of defining materials, methods, and future clinical approaches. The authors enumerate the varied problems in the development of radioimmunoglobulin therapy, and report on the current status of clinical trials.
放射免疫球蛋白疗法是一种新的治疗方式，给药方便，耐受性良好，且可在门诊进行。然而，它并非如人们通常认为的那样是一种简单的癌症治疗方法。它融合了免疫学、生理学、放射生物学、化学和物理学等学科，以及肿瘤学，如果要充分发挥放射免疫球蛋白疗法的潜力，就必须对所有这些学科有所了解。在参与这项研究的临床团队仍在确定材料、方法和未来临床方法的过程中，已经实现了部分缓解和完全缓解。作者列举了放射免疫球蛋白疗法发展中存在的各种问题，并报告了临床试验的现状。
